Biblio
“GSK-3β is Dephosphorylated by PP2A in a Leu309 Methylation-Independent Manner.”, J Alzheimers Dis, vol. 49, no. 2, pp. 365-75, 2016.
, “Prions and Neurodegenerative Diseases: A Focus on Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 503-518, 2022.
, “Propagation of tau pathology in a model of early Alzheimer's disease.”, Neuron, vol. 73, no. 4, pp. 685-97, 2012.
, “Plasma Biomarkers of Alzheimer's Disease in African Americans.”, J Alzheimers Dis, vol. 79, no. 1, pp. 323-334, 2021.
, “An Introduction to Ultrasensitive Assays for Plasma Tau Detection.”, J Alzheimers Dis, vol. 80, no. 4, pp. 1353-1362, 2021.
, “Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms.”, J Alzheimers Dis, vol. 61, no. 1, pp. 169-183, 2018.
, “Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease.”, N Engl J Med, vol. 370, no. 4, pp. 311-21, 2014.
, “The Presence of Select Tau Species in Human Peripheral Tissues and Their Relation to Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 2, pp. 345-56, 2016.
, “Region-Specific Vulnerability to Oxidative Stress, Neuroinflammation, and Tau Hyperphosphorylation in Experimental Diabetes Mellitus Mice.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1209-24, 2016.
, “The Right Temporal Variant of Frontotemporal Dementia Is Not Genetically Sporadic: A Case Series.”, J Alzheimers Dis, vol. 79, no. 3, pp. 1195-1201, 2021.
, “Multifunctional Effect of Human Serum Albumin Reduces Alzheimer's Disease Related Pathologies in the 3xTg Mouse Model.”, J Alzheimers Dis, vol. 50, no. 1, pp. 175-88, 2016.
, “Associations between Use of Specific Analgesics and Concentrations of Amyloid-β 42 or Phospho-Tau in Regions of Human Cerebral Cortex.”, J Alzheimers Dis, vol. 61, no. 2, pp. 653-662, 2018.
, “18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease.”, Brain, vol. 134, no. Pt 4, pp. 1089-100, 2011.
, “The Heritability of Frontotemporal Lobar Degeneration: Validation of Pedigree Classification Criteria in a Northern Italy Cohort.”, J Alzheimers Dis, vol. 61, no. 2, pp. 753-760, 2018.
, “Naphthoquinone-Tryptophan Hybrid Inhibits Aggregation of the Tau-Derived Peptide PHF6 and Reduces Neurotoxicity.”, J Alzheimers Dis, vol. 51, no. 1, pp. 165-78, 2016.
, “Interaction Between Arteriosclerosis and Amyloid-β on Cognitive Function.”, J Alzheimers Dis, vol. 97, no. 2, pp. 953-961, 2024.
, “Influence of Butyrylcholinesterase in Progression of Mild Cognitive Impairment to Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 3, pp. 1097-1105, 2018.
, “A Blood Test for Alzheimer's Disease: It's about Time or Not Ready for Prime Time?”, J Alzheimers Dis, vol. 90, no. 3, pp. 963-966, 2022.
, “Association of Cerebrospinal Fluid (CSF) Insulin with Cognitive Performance and CSF Biomarkers of Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 1, pp. 309-320, 2018.
, “Differences in Synaptic Dysfunction Between rTg4510 and APP/PS1 Mouse Models of Alzheimer's Disease.”, J Alzheimers Dis, vol. 61, no. 1, pp. 195-208, 2018.
, “Cycloheximide Treatment Causes a ZVAD-Sensitive Protease-Dependent Cleavage of Human Tau in Drosophila Cells.”, J Alzheimers Dis, vol. 49, no. 4, pp. 1161-8, 2016.
, “Cognitive Variability Predicts Incident Alzheimer's Disease and Mild Cognitive Impairment Comparable to a Cerebrospinal Fluid Biomarker.”, J Alzheimers Dis, vol. 61, no. 1, pp. 79-89, 2018.
, “Anti-Correlated Cerebrospinal Fluid Biomarker Trajectories in Preclinical Alzheimer's Disease.”, J Alzheimers Dis, vol. 51, no. 4, pp. 1085-97, 2016.
, “Associations of the Harvard Automated Phone Task and Alzheimer's Disease Pathology in Cognitively Normal Older Adults: Preliminary Findings.”, J Alzheimers Dis, vol. 94, no. 1, pp. 217-226, 2023.
, “Differential Diagnosis of Dementia with High Levels of Cerebrospinal Fluid Tau Protein.”, J Alzheimers Dis, vol. 51, no. 3, pp. 905-13, 2016.
,